Cystic Fibrosis
Conditions
Keywords
Patient with Cystic Fibrosis, Patient without Cystic fibrosis
Brief summary
The aim of our study is to assess miRNAs expression profiles in the circuling blood of patients with cystic fibrosis and highlight "signatures" that could reflect the pulmonary status of patients
Detailed description
The objective of this project is to study the circulating miRNA profiles in 40 patients with cystic fibrosis (5 samples which are acquired through a secondary use) and 40 healthy individuals to assess whether these biomolecules could be used as markers of the pulmonary disease in cystic fifbosis. Moreover by comparing miRNAs expression level between Cystic fibrosis (CF) patients with severe (n=20) or moderate (n=20) pulmonary impairment, we want to assess whether some of these miRNAs may be used as markers for the severity of CF pulmonary disease. The identification of sensitive and early markers, from a non-invasive sampling could enable more effective and early treatment of CF patients.
Interventions
OTHERmiRNAs isolation from blood samples of patients and control
Blood sample collection in specific PAXGene tubes
Sponsors
University Hospital, Montpellier
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Months to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with Cystic fibrosis (CF) (MIM#219700) who are compound heterozygous or homozygous for CF causing mutations Healthy controls non -smokers and free pulmonary disease
Exclusion criteria
* Participation or within the exclusion period of other clinicals trials Patients carrying mutations of clinical varying consequences or non CF-causing mutations * smokers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of miRNAs expression between Cystic Fibrosis (CF) patients and healthy controls | After blood collection: 2 years | Compare the distributions of miRNAs expression in blood samples of CF patients and to healthy controls |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assesment of miRNAs expression in Cystic Fibrosis Patients depending on the pulmonary status | After blood collection 2 years | Compare the distributions of miRNAs expression in blood samples of CF patients with mild lung disease and CF patients with severe lung disease |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORCaroline RAYNAL, PharmD, PhD
Montpellier University Hospital (CHU Montpellier) Montpellier University
Outcome results
None listed